<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36059441</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients - a comparative long term post-infection study.</ArticleTitle><Pagination><StartPage>915338</StartPage><MedlinePgn>915338</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">915338</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.915338</ELocationID><Abstract><AbstractText Label="BACKGROUND">Since December 2019, SARS-CoV-2 has been keeping the world in suspense. Rapid tests, molecular diagnosis of acute infections, and vaccination campaigns with vaccines are building blocks of strategic pandemic control worldwide. For laboratory diagnostics, the quantification of the antibody titer of convalescents and vaccinated patients is thus increasingly coming to the fore.</AbstractText><AbstractText Label="METHODS">Here we present an evaluation on the comparability of five serological tests on a cohort of 13 patients with mild COVID-19 disease. Also participants who were vaccinated after recovery were included in this study. All common immune methods (ELISA, CLIA, PETIA) and SARS-CoV-2 specific antigens (N-, S1- and RBD-) were specifically tracked and directly compared for up to 455 days. The titer of recovered participants was also set to the degree of symptoms during infection and the occurrence of Long-COVID. In addition, relative comparability of different serological tests, all standardized to WHO, was set in reference to the neutralizing potential of the corresponding participants.</AbstractText><AbstractText Label="FINDINGS">The individual immune responses over 455 days after a mild SARS-CoV-2 infection remain stable, in contrast to vaccinated participants. All sero-tests reveal comparable performance and dynamics during the study and compared well to a surrogate neutralization test.</AbstractText><AbstractText Label="CONCLUSION">The information presented here will help clinicians in the daily laboratory work in the selection and evaluation of different serological tests offered. The data also will support in respect of a sero-test-based neutralization cutoff.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Brehm, Spaeth, Dre&#xdf;ler, Masetto, Dannenberg, Peter and Grimmler.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brehm</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MVZ Medizinische Labore Dessau Kassel GmbH, Dessau-Ro&#xdf;lau, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spaeth</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MVZ Medizinische Labore Dessau Kassel GmbH, Dessau-Ro&#xdf;lau, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dre&#xdf;ler</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MVZ Medizinische Labore Dessau Kassel GmbH, Dessau-Ro&#xdf;lau, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masetto</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine I, Medical Faculty, Heinrich Heine University D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DiaSys Diagnostic Systems GmbH, Holzheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dannenberg</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>MVZ Medizinische Labore Dessau Kassel GmbH, Dessau-Ro&#xdf;lau, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peter</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine I, Medical Faculty, Heinrich Heine University D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmler</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DiaSys Diagnostic Systems GmbH, Holzheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hochschule Fresenius gGmbH, University of Applied Sciences, Idstein, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">long-term assay comparison</Keyword><Keyword MajorTopicYN="N">mild progression COVID-19</Keyword><Keyword MajorTopicYN="N">neutralizing potential</Keyword><Keyword MajorTopicYN="N">quantification immune response</Keyword></KeywordList><CoiStatement>Authors JB, AS, LD, RD are employed by MVZ Medizinische Labore Dessau Kassel GmbH. Authors TM and MG are employees of DiaSys Diagnostic GmbH and are named as inventors on a patent application (Deutsche Patentanmeldung 10 2020 122 593.8), claiming the manufacturing and use of the described PETIA for serological quantification of SARS-CoV-2 antigens. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The PETIA SARS-CoV-2 UTAB FS assay used in this study was kindly provided by DiaSys Diagnostic Systems GmbH, Holzheim, Germany.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>5</Day><Hour>3</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36059441</ArticleId><ArticleId IdType="pmc">PMC9428854</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.915338</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med (2020) 382:727&#x2013;33. doi: 10.1056/NEJMoa2001017</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China: A descriptive study. Lancet (2020) 395:507&#x2013;13. doi: 10.1016/S0140-6736(20)30211-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>
COVID-19 map . Johns Hopkins Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/map.html (Accessed March 20, 2022).</Citation></Reference><Reference><Citation>Krammer F, Simon V. Serology assays to manage COVID-19. Science (2020) 368:1060&#x2013;1. doi: 10.1126/science.abc1227</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1227</ArticleId><ArticleId IdType="pubmed">32414781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohn MK, Loh TP, Wang C-B, Mueller R, Koch D, Sethi S, et al. . IFCC interim guidelines on serological testing of antibodies against SARS-CoV-2. Clin Chem Lab Med (2020) 58:2001&#x2013;8. doi: 10.1515/cclm-2020-1413</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-1413</ArticleId><ArticleId IdType="pubmed">33027043</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. . Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev (2020) 6:CD013652. doi: 10.1002/14651858.CD013652</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013652</ArticleId><ArticleId IdType="pmc">PMC7387103</ArticleId><ArticleId IdType="pubmed">32584464</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med (2020) 26:845&#x2013;8. doi: 10.1038/s41591-020-0897-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuaillon E, Bollor&#xe9; K, Pisoni A, Debiesse S, Renault C, Marie S, et al. . Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. J Infect (2020) 81:e39&#x2013;45. doi: 10.1016/j.jinf.2020.05.077</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.077</ArticleId><ArticleId IdType="pmc">PMC7834649</ArticleId><ArticleId IdType="pubmed">32504735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. . Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (2020) 370:1227&#x2013;30. doi: 10.1126/science.abd7728</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd7728</ArticleId><ArticleId IdType="pmc">PMC7810037</ArticleId><ArticleId IdType="pubmed">33115920</ArticleId></ArticleIdList></Reference><Reference><Citation>Korte W, Buljan M, R&#xf6;sslein M, Wick P, Golubov V, Jentsch J, et al. . SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on. J Infect (2021) 82:e11&#x2013;4. doi: 10.1016/j.jinf.2020.08.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.032</ArticleId><ArticleId IdType="pmc">PMC7445467</ArticleId><ArticleId IdType="pubmed">32853597</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first report. J Infect (2020) 81:147&#x2013;78. doi: 10.1016/j.jinf.2020.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.012</ArticleId><ArticleId IdType="pmc">PMC7118534</ArticleId><ArticleId IdType="pubmed">32209385</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. . Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis (2020) 71:778&#x2013;85. doi: 10.1093/cid/ciaa310</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa310</ArticleId><ArticleId IdType="pmc">PMC7184472</ArticleId><ArticleId IdType="pubmed">32198501</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. . Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect (2020) 9:940&#x2013;8. doi: 10.1080/22221751.2020.1762515</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1762515</ArticleId><ArticleId IdType="pmc">PMC7273175</ArticleId><ArticleId IdType="pubmed">32357808</ArticleId></ArticleIdList></Reference><Reference><Citation>To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. . Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis (2020) 20:565&#x2013;74. doi: 10.1016/S1473-3099(20)30196-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30196-1</ArticleId><ArticleId IdType="pmc">PMC7158907</ArticleId><ArticleId IdType="pubmed">32213337</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura AD, da Costa HHM, Correa VA, de S, Lima AK, Lindoso JAL, et al. . Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. Sci Rep (2021) 11:17642. doi: 10.1038/s41598-021-95045-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95045-z</ArticleId><ArticleId IdType="pmc">PMC8417219</ArticleId><ArticleId IdType="pubmed">34480056</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaeth A, Masetto T, Brehm J, Wey L, Kochem C, Brehm M, et al. . Characterization of the diagnostic performance of a novel COVID-19 PETIA in comparison to four routine n-, s- and RBD-antigen based immunoassays. Diagnostics (Basel) (2021) 11:1332. doi: 10.3390/diagnostics11081332</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11081332</ArticleId><ArticleId IdType="pmc">PMC8394885</ArticleId><ArticleId IdType="pubmed">34441268</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol Biol (2015) 1282:1&#x2013;23. doi: 10.1007/978-1-4939-2438-7_1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2438-7_1</ArticleId><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: Mechanisms of coronavirus cross-species transmission. J Virol (2010) 84:3134&#x2013;46. doi: 10.1128/JVI.01394-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01394-09</ArticleId><ArticleId IdType="pmc">PMC2838128</ArticleId><ArticleId IdType="pubmed">19906932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res (1997) 48:1&#x2013;100. doi: 10.1016/S0065-3527(08)60286-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-3527(08)60286-9</ArticleId><ArticleId IdType="pmc">PMC7130985</ArticleId><ArticleId IdType="pubmed">9233431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorkhali R, Koirala P, Rijal S, Mainali A, Baral A, Bhattarai HK. Structure and function of major SARS-CoV-2 and SARS-CoV proteins. Bioinform Biol Insights (2021) 15:11779322211025876. doi: 10.1177/11779322211025876</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11779322211025876</ArticleId><ArticleId IdType="pmc">PMC8221690</ArticleId><ArticleId IdType="pubmed">34220199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (2020) 367:1260&#x2013;3. doi: 10.1126/science.abb2507</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med (2020) 26:1033&#x2013;6. doi: 10.1038/s41591-020-0913-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0913-5</ArticleId><ArticleId IdType="pmc">PMC8183627</ArticleId><ArticleId IdType="pubmed">32398876</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol (2020) 5:eabc8413. doi: 10.1126/sciimmunol.abc8413</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abc8413</ArticleId><ArticleId IdType="pmc">PMC7292505</ArticleId><ArticleId IdType="pubmed">32527802</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacol Sin (2020) 41:1141&#x2013;9. doi: 10.1038/s41401-020-0485-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0485-4</ArticleId><ArticleId IdType="pmc">PMC7396720</ArticleId><ArticleId IdType="pubmed">32747721</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Hogan CA, Verghese M, Solis D, Sibai M, Huang C, et al. . SARS-CoV-2 nucleocapsid plasma antigen for diagnosis and monitoring of COVID-19. Clin Chem (2021) 68:204&#x2013;13. doi: 10.1093/clinchem/hvab216</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/hvab216</ArticleId><ArticleId IdType="pmc">PMC8522398</ArticleId><ArticleId IdType="pubmed">34605900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Ong CM, Yun C, Mo W, Whitman JD, Lynch KL, et al. . Diagnostic value of nucleocapsid protein in blood for SARS-CoV-2 infection. Clin Chem (2021) 68:240&#x2013;8. doi: 10.1093/clinchem/hvab148</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/hvab148</ArticleId><ArticleId IdType="pmc">PMC8436384</ArticleId><ArticleId IdType="pubmed">34358289</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lai D, Zhang H, Jiang H, Tian X, Ma M, et al. . Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol (2020) 17:1095&#x2013;7. doi: 10.1038/s41423-020-00523-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00523-5</ArticleId><ArticleId IdType="pmc">PMC7475724</ArticleId><ArticleId IdType="pubmed">32895485</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med (2020) 26:1200&#x2013;4. doi: 10.1038/s41591-020-0965-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0965-6</ArticleId><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zuiani A, Fischinger S, Mullur J, Atyeo C, Travers M, et al. . Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell (2020) 183:1496&#x2013;1507.e16. doi: 10.1016/j.cell.2020.10.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.051</ArticleId><ArticleId IdType="pmc">PMC7608032</ArticleId><ArticleId IdType="pubmed">33171099</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y, Liu T, Wei Y, Li J, Shao L, Liu M, et al. . Scoring systems for predicting mortality for severe patients with COVID-19. EClinicalMedicine (2020) 24:100426. doi: 10.1016/j.eclinm.2020.100426</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100426</ArticleId><ArticleId IdType="pmc">PMC7332889</ArticleId><ArticleId IdType="pubmed">32766541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol (2020) 101:791&#x2013;7. doi: 10.1099/jgv.0.001439</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001439</ArticleId><ArticleId IdType="pmc">PMC7641391</ArticleId><ArticleId IdType="pubmed">32430094</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. . Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol (2021) 147:545&#x2013;57.e9. doi: 10.1016/j.jaci.2020.10.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.040</ArticleId><ArticleId IdType="pmc">PMC7677074</ArticleId><ArticleId IdType="pubmed">33221383</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. . Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis (2020) 71:2027&#x2013;34. doi: 10.1093/cid/ciaa344</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa344</ArticleId><ArticleId IdType="pmc">PMC7184337</ArticleId><ArticleId IdType="pubmed">32221519</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. . Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis (2021) 223:197&#x2013;205. doi: 10.1093/infdis/jiaa618</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa618</ArticleId><ArticleId IdType="pmc">PMC7543487</ArticleId><ArticleId IdType="pubmed">33535236</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. . Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol (2020) 5:1598&#x2013;607. doi: 10.1038/s41564-020-00813-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00813-8</ArticleId><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. . Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol (2020) 5:eabe5511. doi: 10.1126/sciimmunol.abe5511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe5511</ArticleId><ArticleId IdType="pmc">PMC8050884</ArticleId><ArticleId IdType="pubmed">33033173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Long Q-X, Deng H-J, Hu J, Gao Q-Z, Zhang G-J, et al. . Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clin Infect Dis (2021) 73:e531&#x2013;9. doi: 10.1093/cid/ciaa1143</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1143</ArticleId><ArticleId IdType="pmc">PMC7454328</ArticleId><ArticleId IdType="pubmed">32745196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. . Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild covid-19. N Engl J Med (2020) 383:1085&#x2013;7. doi: 10.1056/NEJMc2025179</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2025179</ArticleId><ArticleId IdType="pmc">PMC7397184</ArticleId><ArticleId IdType="pubmed">32706954</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med (2021) 27:1205&#x2013;11. doi: 10.1038/s41591-021-01377-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia WN, Zhu F, Ong SWX, Young BE, Fong S-W, Le Bert N, et al. . Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: A longitudinal study. Lancet Microbe (2021) 2:e240&#x2013;9. doi: 10.1016/S2666-5247(21)00025-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00025-2</ArticleId><ArticleId IdType="pmc">PMC7987301</ArticleId><ArticleId IdType="pubmed">33778792</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. . Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science (2020) 369:643&#x2013;50. doi: 10.1126/science.abc5902</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc5902</ArticleId><ArticleId IdType="pmc">PMC7299281</ArticleId><ArticleId IdType="pubmed">32540902</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. . Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature (2020) 584:443&#x2013;9. doi: 10.1038/s41586-020-2548-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2548-6</ArticleId><ArticleId IdType="pmc">PMC7584396</ArticleId><ArticleId IdType="pubmed">32668443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y, et al. . Human-IgG-Neutralizing monoclonal antibodies block the SARS-CoV-2 infection. Cell Rep (2020) 32:107918. doi: 10.1016/j.celrep.2020.107918</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107918</ArticleId><ArticleId IdType="pmc">PMC7332464</ArticleId><ArticleId IdType="pubmed">32668215</ArticleId></ArticleIdList></Reference><Reference><Citation>Haveri A, Ekstr&#xf6;m N, Solastie A, Virta C, &#xd6;sterlund P, Isosaari E, et al. . Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol (2021) 51:3202&#x2013;13. doi: 10.1002/eji.202149535</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202149535</ArticleId><ArticleId IdType="pmc">PMC8646652</ArticleId><ArticleId IdType="pubmed">34580856</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, et al. . Neutralizing antibodies against the SARS-CoV-2 delta and omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med (2022) 28:481&#x2013;5. doi: 10.1038/s41591-022-01705-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01705-6</ArticleId><ArticleId IdType="pmc">PMC8938264</ArticleId><ArticleId IdType="pubmed">35051990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. . Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in south Africa: A data linkage study. Lancet (2022) 399:437&#x2013;46. doi: 10.1016/S0140-6736(22)00017-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00017-4</ArticleId><ArticleId IdType="pmc">PMC8769664</ArticleId><ArticleId IdType="pubmed">35065011</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz NA, Corman VM, Echterhoff AKC, M&#xfc;ller MA, Richter A, Schmandke A, et al. . Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun (2021) 12:2117. doi: 10.1038/s41467-021-22351-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22351-5</ArticleId><ArticleId IdType="pmc">PMC8035181</ArticleId><ArticleId IdType="pubmed">33837204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Arora P, Gro&#xdf; R, Seidel A, H&#xf6;rnich BF, Hahn AS, et al. . SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell (2021) 184:2384&#x2013;93.e12. doi: 10.1016/j.cell.2021.03.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.036</ArticleId><ArticleId IdType="pmc">PMC7980144</ArticleId><ArticleId IdType="pubmed">33794143</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni D, Mayora-Neto M, Nadesalingam A, Wells DA, Carnell GW, Ohlendorf L, et al. . Neutralisation hierarchy of SARS-CoV-2 variants of concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholds(2022) (Accessed May 11, 2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940306</ArticleId><ArticleId IdType="pubmed">35330908</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Olivares J, Wells DA, Ferrari M, Chan ACY, Smith P, Nadesalingam A, et al. . Analysis of serological biomarkers of SARS-CoV-2 infection in convalescent samples from severe, moderate and mild COVID-19 cases(2021) (Accessed May 11, 2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8640495</ArticleId><ArticleId IdType="pubmed">34867975</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers MA, Olivo A, Harris BJ, Lark C, Luo X, Berg MG, et al. . Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. J Clin Virol (2022) 147:105080. doi: 10.1016/j.jcv.2022.105080</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105080</ArticleId><ArticleId IdType="pmc">PMC8770247</ArticleId><ArticleId IdType="pubmed">35086043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristiano A, Pieri M, Sarubbi S, Pelagalli M, Calugi G, Tomassetti F, et al. . Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring. Clin Immunol (2022) 234:108918. doi: 10.1016/j.clim.2021.108918</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108918</ArticleId><ArticleId IdType="pmc">PMC8714258</ArticleId><ArticleId IdType="pubmed">34971839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. . Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun (2022) 13:446. doi: 10.1038/s41467-021-27797-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-T, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, et al. . SARS-CoV-2 infects human pancreatic &#x3b2; cells and elicits &#x3b2; cell impairment. Cell Metab (2021) 33:1565&#x2013;76.e5. doi: 10.1016/j.cmet.2021.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.05.013</ArticleId><ArticleId IdType="pmc">PMC8130512</ArticleId><ArticleId IdType="pubmed">34081912</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett CE. Risk for newly diagnosed diabetes 30 days after SARS-CoV-2 infection among persons aged 18 years &#x2014; united states, march 1, 2020&#x2013;June 28, 2021. MMWR Morb Mortal Wkly Rep (2022) 71(2):59&#x2013;65. doi:&#xa0;10.15585/mmwr.mm7102e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7102e2</ArticleId><ArticleId IdType="pmc">PMC8757617</ArticleId><ArticleId IdType="pubmed">35025851</ArticleId></ArticleIdList></Reference><Reference><Citation>
Gutenberg COVID-19 studie . Overview. Available at: https://www.unimedizin-mainz.de/gcs/overview.html?L=1 (Accessed March 21, 2022).</Citation></Reference><Reference><Citation>Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. . Long COVID in a prospective cohort of home-isolated patients. Nat Med (2021) 27:1607&#x2013;13. doi: 10.1038/s41591-021-01433-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner AM, Robinson DA, Yang L, Williams CF, Newman LM, Breen JJ, et al. . Toward understanding COVID-19 recovery: National institutes of health workshop on postacute COVID-19. Ann Intern Med (2021) 4(7):999&#x2013;1003. doi: 10.7326/M21-1043</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1043</ArticleId><ArticleId IdType="pmc">PMC8025940</ArticleId><ArticleId IdType="pubmed">33780290</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. . 1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study. Lancet (2021) 398:747&#x2013;58. doi: 10.1016/S0140-6736(21)01755-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch B, Kern-Matschilles S, Haschka SJ, Sacco V, Potzel AL, Banning F, et al. . COVID-19-related symptoms 6 months after the infection - update on a prospective cohort study in Germany. medRxiv (2021) 2021:21251619. doi: 10.1101/2021.02.12.21251619</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.12.21251619</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Henry BM, Plebani M. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role? Clin Chem Lab Med (CCLM) (2021) 59:1885&#x2013;8. doi: 10.1515/cclm-2021-0972</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2021-0972</ArticleId><ArticleId IdType="pubmed">34496165</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera RAPM, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, et al. . Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera. J Clin Microbiol (2021) 59:e02504&#x2013;20. doi: 10.1128/JCM.02504-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02504-20</ArticleId><ArticleId IdType="pmc">PMC8111130</ArticleId><ArticleId IdType="pubmed">33139421</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nsterk&#xf6;tter L, Hollstein MM, Hahn A, Kr&#xf6;ger A, Schnelle M, Erpenbeck L, et al. . Comparison of the anti-SARS-CoV-2 surrogate neutralization assays by TECOmedical and DiaPROPH-med with samples from vaccinated and infected individuals. Viruses (2022) 14:315. doi: 10.3390/v14020315</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14020315</ArticleId><ArticleId IdType="pmc">PMC8877287</ArticleId><ArticleId IdType="pubmed">35215912</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. . A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2&#x2013;spike protein&#x2013;protein interaction. Nat Biotechnol (2020) 38:1073&#x2013;8. doi: 10.1038/s41587-020-0631-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Adeli K, Ferrari M, Horvath AR, Koch D, Sethi S, et al. . Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC taskforce recommendations. Clin Chem Lab Med (CCLM) (2020) 58:1053&#x2013;62. doi: 10.1515/cclm-2020-0633</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0633</ArticleId><ArticleId IdType="pubmed">32396137</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D, Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting health-care workers from subclinical coronavirus infection. Lancet Respir Med (2020) 8:e13. doi: 10.1016/S2213-2600(20)30066-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30066-7</ArticleId><ArticleId IdType="pmc">PMC7128440</ArticleId><ArticleId IdType="pubmed">32061333</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO COVID-19 case definition. Available at: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2 (Accessed March 20, 2022).</Citation></Reference><Reference><Citation>Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin Microbiol Infect (2022) 28:202&#x2013;21. doi: 10.1016/j.cmi.2021.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO/BS.2020.2403 establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody. Available at: https://www.who.int/publications/m/item/WHO-BS-2020.2403 (Accessed March 20, 2022).</Citation></Reference><Reference><Citation>
Elecsys&#xae; . Anti-SARS-CoV-2. diagnostics. Available at: https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html.</Citation></Reference><Reference><Citation>
WMA - The World Medical Association . WMA declaration of Helsinki &#x2013; ethical principles for medical research involving human subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (Accessed May 11, 2022).</Citation></Reference><Reference><Citation>Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al. . Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-Head comparison of five quantitative assays. Microbiol Spectr (2021) 9(1):e00247&#x2013;21. doi: 10.1128/Spectrum.00247-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00247-21</ArticleId><ArticleId IdType="pmc">PMC8552734</ArticleId><ArticleId IdType="pubmed">34190591</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. . A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun (2020) 11:4704. doi: 10.1038/s41467-020-18450-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18450-4</ArticleId><ArticleId IdType="pmc">PMC7499300</ArticleId><ArticleId IdType="pubmed">32943637</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. . Seasonal coronavirus protective immunity is short-lasting. Nat Med (2020) 26:1691&#x2013;3. doi: 10.1038/s41591-020-1083-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1083-1</ArticleId><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>
&#x2018;Immunity passports&#x2019; in the context of COVID-19. Available at: https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19 (Accessed March 20, 2022).</Citation></Reference><Reference><Citation>Naaber P, Tserel L, Kangro K, Sepp E, J&#xfc;rjenson V, Adamson A, et al. . Dynamics of antibody response to BNT162b2 vaccine after six months: longitudinal prospective study. Lancet Regional Health &#x2013; Europe (2021) 10:100208. doi:&#xa0;10.1016/j.lanepe.2021.100208</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100208</ArticleId><ArticleId IdType="pmc">PMC8418937</ArticleId><ArticleId IdType="pubmed">34514454</ArticleId></ArticleIdList></Reference><Reference><Citation>Meschi S, Matusali G, Colavita F, Lapa D, Bordi L, Puro V, et al. . Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine. Clin Chem Lab Med (2021) 59:2010&#x2013;8. doi: 10.1515/cclm-2021-0700</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2021-0700</ArticleId><ArticleId IdType="pubmed">34492749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari D, Mangia A, Span&#xf2; MS, Zaffarano L, Vigan&#xf2; M, Resta CD, et al. . Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign. Clin Chem Lab Med (CCLM) (2021) 59:2019&#x2013;26. doi: 10.1515/cclm-2021-0364</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2021-0364</ArticleId><ArticleId IdType="pubmed">34614550</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. . SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med (2021) 385:1627&#x2013;9. doi: 10.1056/NEJMc2113468</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2113468</ArticleId><ArticleId IdType="pmc">PMC8461567</ArticleId><ArticleId IdType="pubmed">34525276</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Guerrero-Arguero I, Velasco JV, Ver AT, Santos de Oliveira MH, Catahay JA, et al. . Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J Med Virol (2022) 94(7):2939&#x2013;61. doi:&#xa0;10.1002/jmv.27688</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27688</ArticleId><ArticleId IdType="pmc">PMC9088566</ArticleId><ArticleId IdType="pubmed">35229324</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x2019;Huillier AG, Meyer B, Andrey DO, Arm-Vernez I, Baggio S, Didierlaurent A, et al. . Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. Clin Microbiol Infection (2021) 27:784.e1&#x2013;8. doi: 10.1016/j.cmi.2021.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7816882</ArticleId><ArticleId IdType="pubmed">33482352</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis C, Logan N, Tyson G, Orton R, Harvey WT, Perkins JS, et al. . Reduced neutralisation of the delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog (2021) 17:e1010022. doi: 10.1371/journal.ppat.1010022</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010022</ArticleId><ArticleId IdType="pmc">PMC8639073</ArticleId><ArticleId IdType="pubmed">34855916</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Mattiuzzi C, Henry BM. Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 omicron (B.1.1.529) variant. J Med Virol (2022) 94:1799&#x2013;802. doi: 10.1002/jmv.27575</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27575</ArticleId><ArticleId IdType="pmc">PMC9015583</ArticleId><ArticleId IdType="pubmed">34988998</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliari M, Mazzetto E, Gastaldelli M, Bortolami A, Don&#xe0; D, Padoan A, et al. . Omicron neutralizing and anti-SARS-CoV-2 s-RBD antibodies. In: Na&#xef;ve and convalescent populations after homologous and heterologous boosting with an mRNA vaccine. Rochester, NY: Social Science Research Network; (2022). doi:&#xa0;10.2139/ssrn.4016530</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4016530</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med (2021) 27:2032&#x2013;40. doi: 10.1038/s41591-021-01540-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>